Allurion Technologies, Inc 8-K, filed Jul 23, 2026
Allurion Technologies, Inc. (ALUR)
About this 8-K
Allurion Technologies, Inc filed this 8-K on July 23, 2026, reporting on events of July 17, 2026.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
|||
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 17, 2026, Shantanu K. Gaur, M.D. notified Allurion Technologies, Inc. (the “Company”) of his resignation as Chief Executive Officer of the Company and as a member of the Company's board of directors (the “Board”), in each case effective immediately.
Dr. Gaur's resignation was not the result of any disagreement with the Company or the Board on any matter relating to the Company's operations, policies or practices.
In connection with Dr. Gaur's resignation, the Board has not appointed an interim or permanent Chief Executive Officer. Ojas Buch, the Company's Chief Operating Officer, will oversee the Company's day-to-day operations, including certain responsibilities previously performed by Dr. Gaur. Mr. Buch’s title and compensation arrangements have not been modified in connection with these responsibilities.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
Date: |
July 23, 2026 |
By: |
/s/ Brendan M. Gibbons |
|
|
|
Name: Brendan M. Gibbons |